Rama Chellappa, PhD, John Hopkins University Bloomberg Distinguished Professor in electrical, computer, and biomedical engineering, and co-author of “Can We Trust AI?” looks at the promise of AI in health care and how we can best utilize this extraordinary tool to save lives and improve health equity.
The FDA is asking stakeholders to submit public comments on how it should use any portion of the user fee funding that may be distributed to external organizations—other than NEST—to support premarket RWE in medical device evaluation and development.
Under the leadership of Jeff Thompson, MD, Gundersen Health System reduced its greenhouse gases by 95% and was nationally recognized for higher quality care and lower costs. Here Dr. Thompson and Urvashi Bhatnagar, DPT, MBA, author of The Sustainability Scorecard: How Firms can Implement and Profit from Unexpected Solutions, share the strategies and organizational mindset needed to advance sustainability in health care.
MedTech IoT start-ups and early-stage innovators often launch with a minimum viable product, or MVP, a version with just enough features and stability to be used in clinical or field-testing. With the right MVP, companies can prove technical feasibility and position themselves for success with investors. Here is how to get there.
“We are extremely fortunate to have the opportunity to engage with Mark King in this particular phase of the company’s growth. My partner, Eric Wilhelm, and I hope to leverage Mark’s knowledge and experience to help realize the exciting vision we have had for more than a decade as individual business owners and for KMM Group.”
Connectivity in medical devices creates new diagnostic and treatment opportunities, yet at the same time increases the risks of cyberattacks—including their consequences for patient safety and data privacy. Now the new IEC 81001-5-1 standard provides clear technical requirements for manufacturers and developers to ensure the cybersecurity of their products across their life cycle.
“The Liver-Chip detected nearly 7 out of every 8 drugs that proved hepatoxic in clinical use despite having been deemed to have an appropriate therapeutic window by animal models.”
Digital transformation requires a clear vision, buy-in at every level, and significant investment. Here are three steps to streamline the process.
The acquisition expands Veranex’s footprint for product design engineering services across the U.S., with combined company offices now in the Eastern, Central, and Western regions
The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.
